Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Non Operating Income (2016 - 2025)

International Stem Cell (ISCO) has disclosed Non Operating Income for 15 consecutive years, with -$35000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Non Operating Income fell 197.22% to -$35000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $458000.0, a 15166.67% increase, with the full-year FY2023 number at $532000.0, up 4192.31% from a year prior.
  • Non Operating Income was -$35000.0 for Q3 2024 at International Stem Cell, down from $5000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $622000.0 in Q2 2021 to a low of -$1.0 million in Q4 2021.
  • A 5-year average of $29315.8 and a median of $5000.0 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 9527.27% in 2021, then surged 10580.0% in 2023.
  • International Stem Cell's Non Operating Income stood at $11000.0 in 2020, then crashed by 9527.27% to -$1.0 million in 2021, then skyrocketed by 99.52% to -$5000.0 in 2022, then soared by 10580.0% to $524000.0 in 2023, then crashed by 106.68% to -$35000.0 in 2024.
  • Per Business Quant, the three most recent readings for ISCO's Non Operating Income are -$35000.0 (Q3 2024), $5000.0 (Q2 2024), and -$36000.0 (Q1 2024).